Sun Pharmaceutical today said its subsidiary has received approval from the US health regulator to market Bupropion Hydrochloride antidepressants tablets.
The US-based subsidiary of the company has received Food and Drug Administration approval to market its drug Bupropion Hydrochloride Bupropion Hydrochloride Extended-Release, Sun Pharmaceutical said in a filing to the Bombay Stock Exchange.
These tablets are available in strengths of 100 mg, 150 mg and 200 mg, the filing added.
Bupropion Hydrochloride Extended-Release tablets are used for the treatment of major depressive disorder.
These tablets are generic equivalent of GlaxoSmithKline's Wellbutrin SR tablets.
